Gene fusions have a pivotal role in non-small cell lung cancer (NSCLC) precision medicine.
Several techniques can be used, from fluorescence in situ hybridization and …

Several observations indicate that protein expression analysis by immunohistochemistry
(IHC) remains relevant in individuals with non-small-cell lung cancer (NSCLC) when …

Abstract Introduction The Blood First Assay Screening Trial is an ongoing open-label,
multicohort study, prospectively evaluating the relationship between blood-based next …

Objectives The number of targeted drugs in non-small cell lung cancer (NSCLC) is ever-
expanding and requires testing of an increasing number of predictive biomarkers. We …

In 2011, the Vysis Break Apart ALK fluorescence in situ hybridization (FISH) assay was
approved by the United States Food and Drug Administration as a companion diagnostic for …

Fusion genes formed by chromosomal rearrangements are common drivers of cancer.
Recent innovations in the field of next‐generation sequencing (NGS) have seen a dynamic …

Chimeric transcripts are critical for diagnosis or prognosis and could constitute effective
therapeutic targets. Fresh tissues are the major source for the identification of these fusion …

Introduction Next-generation sequencing (NGS) is currently widely used for biomarker
studies and molecular profiling to identify concurrent alterations that can lead to the better …

Background Genomic profiling is needed to identify actionable alterations in non–small cell
lung cancer (NSCLC). Panel‐based testing such as next‐generation sequencing (NGS) is …

Deciphering cancer etiopathogenesis has proven to be an especially challenging task since
the mechanisms that drive tumor development and progression are far from simple. An …